Skip to content

Open for responses

Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination

DEPT OF DEFENSE

Notice type
Solicitation
Solicitation #
HT9427-26-R-E020
NAICS
541715
PSC
AN13
Posted
November 10, 2026
Response due
November 20, 2026
Place of performance
28360, MD

What this opportunity is

The Department of Defense is seeking a contractor to develop a prototype for a Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination product, which must include both a physical barrier and antimicrobial properties. This opportunity is suited for small businesses under NAICS 541715, particularly those with capabilities in medical product development and FDA approval processes. Interested firms should note that this is a solicitation notice, indicating they should track the opportunity closely for updates and amendments, including a revised proposal due date of November 20, 2026.

Analysis by Mindy, grounded in the SAM.gov notice.

Description

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022. NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date). Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026 to: 12:00pm eastern Friday, 06 Nov 2026 Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20 Nov 2026

Source: SAM.gov, as posted. Verify the current solicitation before responding.

Pursue this opportunity with Mindy

See who holds it now, who else is bidding, and draft your response — grounded in real government data, not generic AI.

View the original notice on SAM.gov ↗

Open opportunities in NAICS 541715